Hypertriglyceridemia is an augmented level of triglycerides, a type of lipid, in the bloodstream. It is a condition that enhances the risk of coronary artery disease in human beings. Found in bloodstream, triglycerides is a combination of triglycerides obtained from the diet and those produced to serve as source of energy. Hypertriglyceridemia is usually worsened or caused by various factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, dementia, loss of memory, difficulty in breathing, and gastrointestinal pain are some of the symptoms of hypertriglyceridemia. Treatment of hypertriglyceridemia comprises corticosteroids, estrogen therapy, beta-blockers, and diuretics.
This report contains market size and forecasts of Hypertriglyceridemia Therapeutic in Global, including the following market information:
Global Hypertriglyceridemia Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hypertriglyceridemia Therapeutic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Statins Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hypertriglyceridemia Therapeutic include Sanofi, GlaxoSmithKline, Biocon, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Oramed Pharmaceuticals, Merck, Julphar and Eli Lilly and Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypertriglyceridemia Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypertriglyceridemia Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hypertriglyceridemia Therapeutic Market Segment Percentages, by Type, 2021 (%)
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
Others
Global Hypertriglyceridemia Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hypertriglyceridemia Therapeutic Market Segment Percentages, by Application, 2021 (%)
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Global Hypertriglyceridemia Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hypertriglyceridemia Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypertriglyceridemia Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hypertriglyceridemia Therapeutic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
GlaxoSmithKline
Biocon
Novo Nordisk
Tonghua Dongbao Pharmaceutical
Oramed Pharmaceuticals
Merck
Julphar
Eli Lilly and Company
Bristol-Myers Squibb Company
Pfizer
AbbVie